Peter Burgard1, Stefan Kölker2, Gisela Haege2, Martin Lindner3, Georg F Hoffmann2. 1. Centre for Paediatric and Adolescent Medicine, Division for Neuropaediatrics and Metabolic Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 430, D-69120, Heidelberg, Germany. peter.burgard@med.uni-heidelberg.de. 2. Centre for Paediatric and Adolescent Medicine, Division for Neuropaediatrics and Metabolic Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 430, D-69120, Heidelberg, Germany. 3. University Hospital Frankfurt, Children's Hospital, Theodor-Stern-Kai 7, D-60590, Frankfurt am Main, Germany.
Abstract
BACKGROUND: For urea cycle disorders (UCD), proportions and mortality of early onset (EO) patients, as well as outcome at one year of life show large variability. We aimed to integrate available evidence to create benchmarks for new diagnostic and therapeutic strategies. METHODS: Medline search for reports published between 1978 and Dec 22, 2014 was completed by hand search. Random effects meta-analysis was done for four UCDs, deficiency of carbamylphosphate synthetase 1 (CPS1D), male/female ornithine transcarbamylase (OTCDm/f), argininosuccinate synthetase (ASSD) and lyase (ASLD). Effects of publication year and geographic area were analysed by meta-regression. RESULTS: Twenty-four publications report onset time (n = 1542 patients), survival of EO (n = 665 patients) and outcome at one year of life (n = 172 patients). Proportions for EO manifestation (95% confidence interval) were: CPS1D = 0.75 (0.61;0.88); OTCDm = 0.52 (0.39;0.65); OTCDf = 0.07 (0.03;0.11); ASSD = 0.65 (0.57;0.73); ASLD = 0.60 (0.44;0.77); for surviving EO patients: CPS1D = 0.64 (0.50;0.79); OTCDm = 0.40 (0.16;0.64); OTCDf = 0.57 (0.29;0.85); ASSD = 0.67 (0.48;0.86); ASLD = 0.81 (0.68;0.94); and for normal outcome at one year for survivors: CPS1D = 0.20 (0.07;0.38); OTCDm = 0.15 (0.00;0.39); OTCDf no data; ASSD = 0.36 (0.13;0.60); ASLD = 0.36 (0.17;0.58). Between study variation was large. Year of publication had no effect. Studies from Europe showed lower survival rates than those from Japan or USA. CONCLUSIONS: UCDs, except for OTCDf, have high risks of EO disease manifestation and, except for ASLD, of neonatal death. No improvement of survival was observed over more than three decades. Geographic variation remains to be explained. This comprehensive description of the natural history of EO UCDs should be considered by scientists, clinicians, health policy makers and guideline developers.
BACKGROUND: For urea cycle disorders (UCD), proportions and mortality of early onset (EO) patients, as well as outcome at one year of life show large variability. We aimed to integrate available evidence to create benchmarks for new diagnostic and therapeutic strategies. METHODS: Medline search for reports published between 1978 and Dec 22, 2014 was completed by hand search. Random effects meta-analysis was done for four UCDs, deficiency of carbamylphosphate synthetase 1 (CPS1D), male/female ornithine transcarbamylase (OTCDm/f), argininosuccinate synthetase (ASSD) and lyase (ASLD). Effects of publication year and geographic area were analysed by meta-regression. RESULTS: Twenty-four publications report onset time (n = 1542 patients), survival of EO (n = 665 patients) and outcome at one year of life (n = 172 patients). Proportions for EO manifestation (95% confidence interval) were: CPS1D = 0.75 (0.61;0.88); OTCDm = 0.52 (0.39;0.65); OTCDf = 0.07 (0.03;0.11); ASSD = 0.65 (0.57;0.73); ASLD = 0.60 (0.44;0.77); for surviving EO patients: CPS1D = 0.64 (0.50;0.79); OTCDm = 0.40 (0.16;0.64); OTCDf = 0.57 (0.29;0.85); ASSD = 0.67 (0.48;0.86); ASLD = 0.81 (0.68;0.94); and for normal outcome at one year for survivors: CPS1D = 0.20 (0.07;0.38); OTCDm = 0.15 (0.00;0.39); OTCDf no data; ASSD = 0.36 (0.13;0.60); ASLD = 0.36 (0.17;0.58). Between study variation was large. Year of publication had no effect. Studies from Europe showed lower survival rates than those from Japan or USA. CONCLUSIONS: UCDs, except for OTCDf, have high risks of EO disease manifestation and, except for ASLD, of neonatal death. No improvement of survival was observed over more than three decades. Geographic variation remains to be explained. This comprehensive description of the natural history of EO UCDs should be considered by scientists, clinicians, health policy makers and guideline developers.
Authors: Gregory M Enns; Susan A Berry; Gerard T Berry; William J Rhead; Saul W Brusilow; Ada Hamosh Journal: N Engl J Med Date: 2007-05-31 Impact factor: 91.245
Authors: Roland Posset; Angeles Garcia-Cazorla; Vassili Valayannopoulos; Elisa Leão Teles; Carlo Dionisi-Vici; Anaïs Brassier; Alberto B Burlina; Peter Burgard; Elisenda Cortès-Saladelafont; Dries Dobbelaere; Maria L Couce; Jolanta Sykut-Cegielska; Johannes Häberle; Allan M Lund; Anupam Chakrapani; Manuel Schiff; John H Walter; Jiri Zeman; Roshni Vara; Stefan Kölker Journal: J Inherit Metab Dis Date: 2016-04-22 Impact factor: 4.982
Authors: Roland Posset; Sven F Garbade; Nikolas Boy; Alberto B Burlina; Carlo Dionisi-Vici; Dries Dobbelaere; Angeles Garcia-Cazorla; Pascale de Lonlay; Elisa Leão Teles; Roshni Vara; Nicholas Ah Mew; Mark L Batshaw; Matthias R Baumgartner; Shawn E McCandless; Jennifer Seminara; Marshall Summar; Georg F Hoffmann; Stefan Kölker; Peter Burgard Journal: J Inherit Metab Dis Date: 2019-01 Impact factor: 4.982
Authors: Susan E Waisbren; David Cuthbertson; Peter Burgard; Amy Holbert; Robert McCarter; Stephen Cederbaum Journal: J Inherit Metab Dis Date: 2018-02-08 Impact factor: 4.982
Authors: Nina Hediger; Markus A Landolt; Carmen Diez-Fernandez; Martina Huemer; Johannes Häberle Journal: J Inherit Metab Dis Date: 2018-03-08 Impact factor: 4.982
Authors: Roland Posset; Andrea L Gropman; Sandesh C S Nagamani; Lindsay C Burrage; Jirair K Bedoyan; Derek Wong; Gerard T Berry; Matthias R Baumgartner; Marc Yudkoff; Matthias Zielonka; Georg F Hoffmann; Peter Burgard; Andreas Schulze; Shawn E McCandless; Angeles Garcia-Cazorla; Jennifer Seminara; Sven F Garbade; Stefan Kölker Journal: Ann Neurol Date: 2019-05-13 Impact factor: 10.422
Authors: Elizabeth G Ames; Corey Powell; Rachel M Engen; Donald J Weaver; Asif Mansuri; Michelle N Rheault; Keia Sanderson; Uta Lichter-Konecki; Ankana Daga; Lindsay C Burrage; Ayesha Ahmad; Scott E Wenderfer; Kera E Luckritz Journal: J Pediatr Date: 2022-03-28 Impact factor: 6.314
Authors: Matthias Zielonka; Sven F Garbade; Florian Gleich; Jürgen G Okun; Sandesh C S Nagamani; Andrea L Gropman; Georg F Hoffmann; Stefan Kölker; Roland Posset Journal: Hum Mutat Date: 2020-01-30 Impact factor: 4.878